174758-16-8

Upstream product

• 64-17-5 ethanol 
• 35761-26-3 (S)-3-amino-2-(((benzyloxy)carbonyl)amino)propanoic acid 

Downstream Products

• 174665-91-9 (2S)-2-Benzyloxycarbonylamino-3-t-butoxycarbonylaminopropanoic acid ethyl ester 
• 336191-04-9 Ethyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({[3-(4-pyridyl)-3-azaspiro [5.5]undec-9-yl]carbonyl}amino)propanoate 
• 488118-61-2 (S)-2-Benzyloxycarbonylamino-3-(2-nitro-phenylamino)-propionic acid ethyl ester 
• 237059-38-0 4-{2-[2-(4-bromo-benzenesulfonylamino)-2-ethoxycarbonyl-ethylcarbamoyl]-1H-indol-5-yloxymethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 237059-39-1 2-(4-bromo-benzenesulfonylamino)-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid ethyl ester 
• 237059-36-8 2-(4-bromo-benzenesulfonylamino)-3-tert-butoxycarbonylamino-propionic acid ethyl ester 
• 237059-37-9 (S)-3-Amino-2-(4-bromo-benzenesulfonylamino)-propionic acid ethyl ester 
• 488118-62-3 (S)-2-Allyloxycarbonylamino-3-(2-amino-phenylamino)-propionic acid ethyl ester 

Relevant academic research and scientific papers

Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same

A subject of the invention is the compounds of formula (I): in which R1, R2, R3, R4 and G have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them.

(1-Benzimidazolonyl)alanine (Bia): Preliminary investigations into a potential tryptophan mimetic

The new amino acid (1-benzimidazolonyl)alanine (Bia) was synthesized as a potential biomimetic replacement of tryptophan. The replacement of tryptophan with this amino acid in a truncated analog of p53 showed nearly identical binding to HDM2 as the same l

Non-peptide fibrinogen receptor antagonists. 4. The synthesis of [3H]L-756,568

The synthesis of [3H]L-756,568, an orally active fibrinogen receptor antagonist, is described. Two synthetic pathways were developed using either bromoindoles 2a/2b or bromoaryl sulfonamide 11 as the precursor. Use of the bromoaryl sulfonamide